Both apigenin and luteolin exhibited efficacy in targeting the PI3K/Akt/mTOR axis, making them as promising non-toxic alternatives to synthetic chemical drugs used for the treatment of CRC (Sain et al., 2022). This evidence concerns the gene AKT1 and colorectal carcinoma.